Business Context and Reporting Period
Company: Phase III Medical, Inc. (filing as Phase III Medical, Inc., formerly Corniche Group Incorporated; note: input metadata referenced "Lisata Therapeutics" but the filing text confirms the registrant is Phase III Medical, Inc.)
Reporting Period: Fiscal year ended December 31, 2005.
Business Overview: The Company historically provided capital and guidance to healthcare companies and operated a "run-off" of an internet-based extended warranty business. Effective January 19, 2006 (subsequent to the reporting period), the Company acquired the assets of NeoStem Inc., shifting its principal business to the collection, processing, and storage of autologous adult stem cells for regenerative medicine.
Key Financial Metrics
| Metric | 2005 | 2004 | 2003 |
|---|---|---|---|
| Revenues | $35,262 | $48,561 | $64,632 |
| Gross Profit | $10,486 | $14,676 | $21,024 |
| Operating Loss | $(1,600,912) | $(1,474,288) | $(894,329) |
| Net Loss | $(1,745,039) | $(1,748,372) | $(1,067,987) |
| Cash Balance (Year End) | $488,872 | $27,868 | $210,947 |
| Working Capital (Deficiency) | $(1,245,084) | $(1,239,000 approx) | $(794,000 approx) |
| Stockholders' Deficit | $(1,817,638) | $(1,931,790) | $(1,502,771) |
| Notes Payable (Current) | $135,000 | $475,000 | N/A |
Note: Revenues are derived entirely from the "run-off" of deferred warranty contracts sold in prior years. The Company has no revenue from its new stem cell business as of December 31, 2005.
Material Changes vs. Prior Period
- Operating Expenses: General and administrative expenses increased by 190% to $1.61 million in 2005 from $764,000 in 2004. This was driven by increased salaries ($495k), legal/accounting fees ($196k), and investment banking fees ($61k).
- Interest Expense: Decreased to $96,580 in 2005 from $226,599 in 2004 due to lower debt levels and favorable terms on loans from officers/directors compared to non-affiliated noteholders in the prior year.
- Capital Raising: The Company raised approximately $1.6 million in 2005 through March 2006 via equity and convertible debt sales to fund operations and the NeoStem acquisition.
- Strategic Shift: While the 2005 financials reflect the legacy business, the Company consummated the acquisition of NeoStem assets on January 19, 2006, fundamentally changing its business model to adult stem cell banking.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: Auditors (Holtz Rubenstein Reminick LLP) have expressed substantial doubt about the Company's ability to continue as a going concern due to recurring losses, a working capital deficiency of $1.25 million, and a stockholders' deficit of $1.82 million.
- Liquidity Needs: The Company requires substantial additional financing to fund the NeoStem business plan, pay assumed liabilities, and cover operating costs. There is no assurance that capital will be available on acceptable terms.
- Regulatory Risks: The new stem cell business is subject to FDA and state regulations (e.g., California biologics license). NeoStem's license was suspended in 2005; the Company is seeking revalidation and a new license. Failure to obtain this license could materially harm the business.
- Market Risks: Success depends on the commercial viability of adult stem cell therapies, which are not yet standard of care for most diseases. The Company faces competition from established cord blood banks and other stem cell providers.
- Intellectual Property: The Company holds two pending patent applications acquired from NeoStem but faces uncertainty regarding patent validity and potential infringement claims.
Investor Verification Checklist
- Capital Adequacy: Verify the status of the $500,000 convertible note offering closed in late 2005/early 2006 and any subsequent financing efforts to address the $1.25 million working capital deficit.
- Regulatory Status: Confirm the current status of the California biologics license application for the NeoStem facility, as operations are contingent upon this approval.
- Debt Obligations: Review the terms of outstanding convertible notes and the $465,000 in assumed NeoStem liabilities, including the portion satisfied by stock issuance.
- Executive Compensation: Note the significant stock-based compensation and deferred salary arrangements for executives (e.g., CEO Mark Weinreb, EVP Catherine Vaczy) and the recent resignation of COO Robert Aholt, Jr., involving a $250,000 settlement.
- Revenue Run-off: Understand that current revenue is purely from legacy warranty contracts and will cease as the run-off completes, with no near-term revenue expected from the stem cell business.